Biological characterization of the therapeutic role of Rab10 modulation in the development of Alzheimer’s disease

Alzheimer’s disease (AD) is the leading cause of dementia in the elderly. The continuous genetic research done on this disease demonstrates the vast complexity of the genetic architecture. The most recent whole‐genome sequence analysis (GWAS)included 1.1 million individuals and identified 38 loci associated with AD status with seven novel loci. However, there is no reliable therapeutics to combat the late stages of AD as of late. The identified rare variants in the RAB10 gene show protective effects against developing AD. This work demonstrates that inhibition of the expression of RAB10 yields better outcomes in terms of the amyloid‐beta ratio and cognition. In addition, we demonstrated that RAB10 modulates the NLRC4 inflammasome complex and their derived products IL‐1‐beta, IL‐18, and TNF‐alpha.